Dylan Dupuis
Stock Analyst at Roth MKM
(2.78)
# 2,013
Out of 5,090 analysts
8
Total ratings
50%
Success rate
43.19%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dylan Dupuis
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CMMB Chemomab Therapeutics | Reinstates: Buy | $28 | $2.48 | +1,029.03% | 2 | Dec 19, 2023 | |
| IVA Inventiva | Reiterates: Buy | $11 | $4.13 | +166.34% | 2 | Sep 21, 2023 | |
| TERN Terns Pharmaceuticals | Reiterates: Buy | $23 | $29.36 | -21.66% | 3 | Aug 8, 2023 | |
| VKTX Viking Therapeutics | Assumes: Buy | $32 | $38.55 | -16.99% | 1 | May 31, 2023 |
Chemomab Therapeutics
Dec 19, 2023
Reinstates: Buy
Price Target: $28
Current: $2.48
Upside: +1,029.03%
Inventiva
Sep 21, 2023
Reiterates: Buy
Price Target: $11
Current: $4.13
Upside: +166.34%
Terns Pharmaceuticals
Aug 8, 2023
Reiterates: Buy
Price Target: $23
Current: $29.36
Upside: -21.66%
Viking Therapeutics
May 31, 2023
Assumes: Buy
Price Target: $32
Current: $38.55
Upside: -16.99%